Tresiba insulin degludec regulatory update

EMA’s CHMP recommended approval of an expanded label for Novo Nordisk’s Tresiba insulin degludec to treat Type I and Type II diabetes to include its use in patients ages 1-17. Novo Nordisk markets the...